GEA
NTLA icon

Glen Eagle Advisors’s Intellia Therapeutics NTLA Stock Holding History

Glen Eagle Advisors’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-50
Closed -$450 – 1049
2025
Q4 		$450 Hold
50
– – ﹤0.01% 1008
2025
Q3 		$864 Hold
50
– – ﹤0.01% 1016
2025
Q2 		$469 Hold
50
– – ﹤0.01% 985
2025
Q1 		$356 Hold
50
– – ﹤0.01% 1014
2024
Q4 		$583 Hold
50
– – ﹤0.01% 1017
2024
Q3 		$1.03K Hold
50
– – ﹤0.01% 1000
2024
Q2 		$1.12K Hold
50
– – ﹤0.01% 981
2024
Q1 		$1.38K Hold
50
– – ﹤0.01% 955
2023
Q4 		$1.52K Hold
50
– – ﹤0.01% 894
2023
Q3 		$1.58K Hold
50
– – ﹤0.01% 891
2023
Q2 		$2.04K Hold
50
– – ﹤0.01% 872
2023
Q1 		$1.86K Buy
+50
New +$1.96K ﹤0.01% 861
2022
Q1 		– Sell
-62
Closed -$7.33K – 967
2021
Q4 		$7.33K Sell
62
-85
-58% -$10.6K ﹤0.01% 666
2021
Q3 		$19.7K Buy
147
+12
+9% +$1.82K 0.01% 561
2021
Q2 		$21.9K Sell
135
-190
-58% -$14.8K 0.01% 541
2021
Q1 		$26.1K Hold
325
– – 0.01% 465
2020
Q4 		$17.7K Hold
325
– – 0.01% 521
2020
Q3 		$6.46K Hold
325
– – ﹤0.01% 663
2020
Q2 		$6.83K Buy
+325
New +$5.52K ﹤0.01% 624

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Glen Eagle Advisors's NTLA Position: Q1 2026 in Review

Glen Eagle Advisors sold out of Intellia Therapeutics (NTLA) in Q1 2026, closing a stake of 50 shares — an estimated $450 sold.

Glen Eagle Advisors first reported a position in NTLA in Q2 2020 and held it in 19 quarters. The position peaked at $26.1K in Q1 2021. 302 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

  • Glen Eagle Advisors reported no remaining Intellia Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Glen Eagle Advisors sold 50 Intellia Therapeutics shares in Q1 2026, an estimated $450.
  • Glen Eagle Advisors first reported a position in Intellia Therapeutics in Q2 2020 and held it in 19 quarters.
  • Glen Eagle Advisors's Intellia Therapeutics position peaked at $26.1K in Q1 2021.
  • 302 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on Glen Eagle Advisors's 13F filing for Q1 2026, filed 15 May 2026.